The Central African Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM) is conducting a post-approval study, designed to gather safety and tolerability information about Pyramax® (pyronaridine-artesunate, developed with Shin Poong) in ‘real-life’ settings, including in young children (under 1 year). The study was requested by the EMA to be carried out in parallel to the launch/scale-up of Pyramax in malaria-endemic countries. So far 84% of patients have been recruited.
The increased breadth of pharmacovigilance and range of safety data collected is expected to support the wider uptake of both Pyramax tablets and granules at country level.
Updated July 2018